What Is KPV? Benefits, Research & Safety
An anti-inflammatory tripeptide derived from alpha-MSH, researched for potent NF-κB inhibition and applications in gut and skin inflammation.
Quick Facts
Overview
Discovery & History
Mechanism of Action
[Molecular Structure Diagram Placeholder]
Researched Benefits
Based on preclinical and clinical research findings:
- 1Potent NF-κB inhibition reducing inflammatory gene expression
- 2Suppression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)
- 3Potential applications in inflammatory bowel disease (colitis models)
- 4Anti-inflammatory effects in skin inflammation models
- 5Small size enabling oral and topical delivery possibilities
- 6Anti-inflammatory activity without melanogenic side effects
Theoretical Dosing & Protocols
| Theoretical Dosage | Research protocols vary; oral and injectable routes studied |
| Frequency | Daily administration in most research protocols |
| Duration | Typically 2-4 weeks in preclinical studies |
| Notes | Nanoparticle formulations studied for targeted gut delivery. No established human dosing protocols exist. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection
- Oral (research)
- Topical (research)
- Nanoparticle delivery (research)
| Half-Life | Stability |
|---|---|
| Short half-life typical of small peptides; exact pharmacokinetic data limited | Relatively stable for a tripeptide; lyophilised form recommended for storage |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Injection site reactions (injectable route)
- Limited human safety data available
Rare Risks & Concerns
- Unknown long-term effects
- Potential immune suppression with chronic use
Contraindications
- Active infections (theoretical)
- Immunocompromised states
- Pregnancy and breastfeeding
UK & EU Regulatory Context
🇬🇧 United Kingdom
Unregulated research peptide. Not approved for human therapeutic use by the MHRA.
🇪🇺 European Union
Not approved by the EMA. Available as a research compound.
Clinical Studies Summary
KPV Anti-Inflammatory Activity in Colitis Models
Preclinical research demonstrated that KPV significantly reduced intestinal inflammation in colitis models, decreasing pro-inflammatory cytokine production and improving mucosal barrier integrity through NF-κB inhibition.
Nanoparticle-Delivered KPV for IBD
Studies explored hyaluronic acid-functionalised nanoparticles loaded with KPV for targeted delivery to inflamed colonic tissue, showing enhanced therapeutic efficacy compared to free KPV in animal models.
Looking for KPV?
Source research-grade KPV from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Related Research Guides
Related Peptides
BPC-157
A pentadecapeptide derived from human gastric juice, extensively researched for its potential tissue repair and regenerative properties across multiple organ systems.
Learn moreThymosin Alpha-1
A thymic peptide with potent immunomodulatory properties, approved in some countries for treating viral hepatitis and as an immune adjuvant.
Learn moreLL-37
The only human cathelicidin antimicrobial peptide, with broad-spectrum antimicrobial activity and important immunomodulatory functions.
Learn moreVIP
A neuropeptide with vasodilatory, anti-inflammatory, and immunomodulatory properties, researched for various therapeutic applications.
Learn moreAlpha-MSH
A melanocortin peptide with pigmentation, anti-inflammatory, and appetite-regulating effects, the natural basis for several therapeutic developments.
Learn more